Pillar Guide · Updated March 2026

GLP-1 Side Effects: The Complete Guide (2026)

GLP-1 medications cause side effects in the majority of users, but most are mild, temporary, and manageable. In the SURMOUNT-1 trial (tirzepatide), 24-31% experienced nausea and only 4.3-7.1% discontinued due to side effects. In the STEP 1 trial (semaglutide 2.4mg), 43.9% reported nausea but 99.5% of gastrointestinal events were classified as non-serious. This guide covers every known side effect, organized by frequency and severity, with data from the major clinical trials published in the New England Journal of Medicine.

How Common Are Side Effects? The Clinical Data

Before getting into specifics, here are the overall rates from the two landmark trials.

Tirzepatide (Mounjaro/Zepbound): SURMOUNT-1 Trial

The SURMOUNT-1 trial published in NEJM enrolled 2,539 adults with obesity. Side effect rates across all tirzepatide doses:

Semaglutide (Ozempic/Wegovy): STEP 1 Trial

The STEP 1 trial published in NEJM enrolled 1,961 adults. Side effect rates for semaglutide 2.4mg:

Key takeaway: Tirzepatide generally has lower GI side effect rates than semaglutide at equivalent weight loss levels. This aligns with what I hear from people in the GLP-1 community and what I have experienced personally on Mounjaro.

Gastrointestinal Side Effects (Most Common)

GI symptoms are by far the most reported side effects. They are also the ones most likely to fade over time.

Nausea (24-44% of users)

Nausea is the single most common GLP-1 side effect. It tends to peak during the first 2-4 weeks on a new dose, then gradually improves as your body adjusts.

What the data shows:

• SURMOUNT-1: 24.6-31.0% of tirzepatide users
• STEP 1: 43.9% of semaglutide users
• Most nausea is mild to moderate
• Only 1.5-3% of patients in clinical trials discontinued due to nausea alone

Management strategies:

• Eat smaller, more frequent meals
• Avoid high-fat and greasy foods (these slow gastric emptying, which GLP-1s already do)
• Stay hydrated. Sip water throughout the day.
• Eat bland foods when nausea is active (crackers, toast, rice, bananas)
• Take your injection before bed so the worst nausea hits while you sleep
• Ask your provider about temporarily holding at a lower dose if nausea is severe

For a detailed breakdown of nausea management, see the nausea section of our GLP-1 side effects timeline guide.

Diarrhea (12-30% of users)

Diarrhea is the second most common GI side effect. Like nausea, it tends to be dose-related and improves over time.

Management strategies:

• Stay hydrated (this is critical with diarrhea)
• Reduce fiber intake temporarily
• Avoid caffeine and alcohol, which can worsen symptoms
• Over-the-counter loperamide (Imodium) is generally safe but check with your provider
• Consider probiotics

Constipation (5-24% of users)

Constipation is more common with semaglutide (24.2% in STEP 1) than tirzepatide (11.7-17.1% in SURMOUNT-1). GLP-1 medications slow gastric motility, which can lead to harder, less frequent stools.

Management strategies:

• Increase water intake to at least 64oz daily
• Add fiber gradually (psyllium husk, fruits, vegetables)
• Move your body daily. Even walking helps gut motility.
• Magnesium citrate (200-400mg daily) is safe and effective for most people
• Stool softeners like docusate sodium if needed

See our GLP-1 constipation guide for the full protocol.

Vomiting (8-25% of users)

Vomiting is more common with semaglutide (24.8%) than tirzepatide (8.3-12.2%). It typically occurs alongside nausea during the first weeks on a new dose.

When to call your doctor: If you are vomiting frequently (more than 2-3 times per day), cannot keep fluids down, or vomiting persists for more than 48 hours, contact your prescribing provider. Dehydration from persistent vomiting is a real risk.

Abdominal Pain and Dyspepsia (5-9% of users)

Upper abdominal pain and indigestion (dyspepsia) affect a smaller percentage of users. These symptoms are usually mild and dose-related.

Injection Site Reactions (3% of users)

About 3% of users in clinical trials reported injection site reactions. These include:

• Redness at the injection site
• Mild swelling or itching
• Bruising
• Pain or tenderness

These reactions are almost always mild and resolve within a few days. Rotating injection sites (abdomen, thigh, upper arm) helps prevent them. If you are getting frequent reactions, switching to a different body area often solves the problem.

For detailed injection technique and troubleshooting, see our injection site reactions guide.

Fatigue and Low Energy (3-11% of users)

Fatigue is reported by 2.9-4.0% of tirzepatide users (SURMOUNT-1) and 11.0% of semaglutide users (STEP 1). There are two common causes:

1. Caloric deficit. GLP-1 medications reduce appetite significantly. If you are eating dramatically less than before, fatigue is an expected result of a large calorie gap.
2. The medication itself. GLP-1 receptor agonists may have some direct effect on energy levels, though the mechanism is not fully understood.

Management strategies:

• Track your calories. Make sure you are eating at least 1,200-1,500 calories daily (more if you are active).
• Prioritize protein (aim for 0.7-1g per pound of lean body mass)
• Stay hydrated
• Get 7-8 hours of sleep
• Light to moderate exercise helps maintain energy

Our GLP-1 fatigue guide covers this in depth.

Hair Loss (2.8-5.7% of users)

Hair loss on GLP-1 medications is a form of telogen effluvium, a temporary condition triggered by rapid weight loss, caloric restriction, or nutritional changes. It is not unique to GLP-1 drugs. Any significant weight loss (10%+ of body weight) can trigger it.

Key facts:

• SURMOUNT-1 reported hair loss in 2.8-5.7% of tirzepatide users (vs. 0.9% placebo)
• The STEP 1 trial did not specifically track hair loss, but post-market reports are common
• It typically begins 3-6 months after starting treatment
• It is temporary. Hair regrowth typically starts 3-6 months after hair loss begins, once your body adjusts to the new weight.
• It is NOT permanent pattern baldness

Management strategies:

• Ensure adequate protein intake (this is the most important factor)
• Take a daily multivitamin with biotin, iron, and zinc
• Avoid crash dieting. Gradual weight loss reduces telogen effluvium risk.
• Consider collagen peptides (the evidence is limited but some people report benefit)

For the full guide on GLP-1 hair loss, including what works and what does not, see our hair loss on GLP-1 guide.

”Ozempic Face” (Facial Volume Loss)

“Ozempic face” is the colloquial term for facial volume loss that can occur with significant weight loss. It is not a medical side effect of the drug itself. It is what happens when you lose a large amount of body fat, including subcutaneous fat in the face.

What you need to know:

• More noticeable with rapid weight loss of 20%+ body weight
• More pronounced in older patients (40+) who have less skin elasticity
• Affects the cheeks, under-eye area, and jawline
• Not specific to semaglutide. Any method of rapid weight loss can cause it.

Prevention and management:

• Gradual weight loss (1-2 lbs per week) allows skin to adapt
• Maintaining muscle mass through resistance training helps preserve facial structure
• Adequate hydration and protein intake
• Dermal fillers are an option for those who want to restore volume (cosmetic, not medical)

The key is gradual weight loss, adequate protein, resistance training, and hydration.

Serious but Rare Side Effects

The following side effects are uncommon but important to understand before starting GLP-1 treatment.

Pancreatitis Risk

Both semaglutide and tirzepatide carry a warning about acute pancreatitis. The actual incidence is very low.

• SURMOUNT-1: 0.2% of tirzepatide users experienced pancreatitis-related events
• STEP 1: Acute pancreatitis was reported in less than 0.5% of semaglutide users
• The FDA requires monitoring and a warning, but the absolute risk is small

Warning signs: Severe, persistent abdominal pain that radiates to the back, often accompanied by nausea and vomiting. If you experience this, stop the medication and seek medical attention immediately.

Risk factors: History of pancreatitis, heavy alcohol use, very high triglycerides (>500 mg/dL), gallstones.

Thyroid Concerns (Medullary Thyroid Carcinoma Warning)

All GLP-1 receptor agonists carry a boxed warning about medullary thyroid carcinoma (MTC). This is based on animal studies (rats and mice) where GLP-1 medications caused thyroid C-cell tumors at high doses.

Important context:

• This has NOT been observed in human clinical trials
• Humans have far fewer GLP-1 receptors on thyroid C-cells than rodents
• The warning exists because it cannot be completely ruled out
• Both semaglutide and tirzepatide are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

If you have a family history of thyroid cancer, discuss this with your doctor before starting GLP-1 treatment.

Gallbladder Issues

Rapid weight loss from any cause increases the risk of gallstone formation. GLP-1 medications can compound this by slowing gallbladder emptying.

• SURMOUNT-1: Gallbladder-related events occurred in 0.4-1.3% of tirzepatide users
• The risk is higher with faster weight loss

Warning signs: Pain in the upper right abdomen, especially after eating fatty foods. Pain that radiates to the right shoulder or back. Nausea and vomiting with abdominal pain.

Muscle Loss

This is not a side effect of the drug, but of rapid weight loss in general. In SURMOUNT-1, approximately 33-39% of weight lost was lean mass (including muscle). The STEP 1 trial showed similar ratios.

I track this personally with DEXA scans. After 6 months on Mounjaro, my results showed I was losing both fat and some lean mass. The key to minimizing muscle loss:

• Resistance training 2-4 times per week (this is non-negotiable)
• Protein intake of 0.7-1g per pound of lean body mass
• Adequate calorie intake (do not go below 1,200-1,500 calories)

Our exercise and muscle guide and DEXA scan results guide cover this in detail.

Side Effect Timeline: What to Expect and When

Understanding the timeline helps you prepare for each phase of treatment.

Weeks 1-4 (Starting Dose)

This is when GI side effects are most noticeable. Your body is adjusting to the medication.

• Most common: Nausea (peak intensity), decreased appetite, mild diarrhea or constipation
• Less common: Fatigue, headache, injection site reactions
• Typical duration: Most GI symptoms improve by week 3-4 on the same dose

Weeks 5-12 (Dose Titration)

Each dose increase can trigger a temporary return of GI symptoms, though usually milder than the initial onset.

• Most common: Brief nausea after dose increase (1-3 days), appetite changes
• Less common: Constipation may worsen as doses increase
• Pattern: Side effects follow a “sawtooth” pattern. They spike briefly after each dose increase and then settle.

Months 3-6

Most GI side effects have faded or become manageable by this point. New concerns may emerge:

• Hair loss may begin (telogen effluvium from rapid weight loss)
• Fatigue can persist if caloric intake is too low
• Facial volume changes may become noticeable with significant weight loss
• Muscle loss becomes a factor if you are not doing resistance training

Months 6-12

By this point, most people have adjusted to their maintenance dose. Ongoing side effects are usually mild. The focus shifts to:

• Maintaining muscle mass through exercise and protein
• Monitoring for any delayed side effects
• Regular lab work to check metabolic markers

When to Call Your Doctor

Contact your prescribing provider immediately if you experience:

• Severe abdominal pain that does not go away (possible pancreatitis)
• Signs of allergic reaction: swelling of face, lips, or throat, difficulty breathing, severe rash
• Persistent vomiting that prevents you from keeping fluids down
• Signs of hypoglycemia if you are also on insulin or sulfonylureas (shakiness, confusion, rapid heartbeat)
• A lump or swelling in your neck (thyroid concerns)
• Severe pain in the upper right abdomen (gallbladder)
• Changes in vision
• Signs of kidney problems: decreased urination, swelling in legs/feet

Do not try to “push through” severe symptoms. Your provider can adjust your dose, slow your titration schedule, or switch you to a different medication.

Side Effects by Medication: Quick Comparison

Tirzepatide has a lower overall GI side effect profile despite producing comparable or greater weight loss. This is one reason many providers now start patients on tirzepatide when possible. For a full medication comparison, see our Mounjaro vs Ozempic breakdown.

FAQ

Do GLP-1 side effects go away?

Yes, for most people. GI side effects (nausea, diarrhea, constipation) typically peak during the first 2-4 weeks on each new dose and then fade. In the SURMOUNT-1 trial, the majority of GI events were classified as mild to moderate and transient. Most people report that side effects become manageable or disappear entirely by month 3-4 on a stable dose.

Which GLP-1 has the fewest side effects?

Tirzepatide (Mounjaro/Zepbound) has lower rates of nausea, diarrhea, vomiting, and constipation compared to semaglutide (Ozempic/Wegovy) in clinical trials, while producing comparable or greater weight loss. Discontinuation rates due to side effects were also lower for tirzepatide (4.3-7.1%) versus semaglutide (7.0%) in their respective trials.

Is hair loss from GLP-1 medications permanent?

No. Hair loss associated with GLP-1 medications is telogen effluvium, a temporary condition triggered by rapid weight loss and caloric changes. Hair regrowth typically begins 3-6 months after the shedding starts, once your body adjusts to the new weight. Adequate protein intake and a multivitamin with biotin help support recovery.

Can GLP-1 medications cause pancreatitis?

Acute pancreatitis has been reported in less than 0.5% of GLP-1 users in clinical trials. The risk is real but low. Patients with a history of pancreatitis, heavy alcohol use, or very high triglycerides should discuss this risk with their doctor. Symptoms include severe, persistent abdominal pain radiating to the back. Stop the medication and seek immediate medical care if this occurs.

Related

Side Effect Guides:

• Nausea Management · Constipation Guide · Injection Site Reactions
• Fatigue Guide · Hair Loss on GLP-1 · Ozempic Face Prevention

Related Guides:

• Exercise and Muscle on GLP-1 · DEXA Scan Results · Side Effects Month by Month
• Mounjaro Dosage Guide · Fat Loss vs Weight Loss
• Best Supplements on GLP-1 · Mounjaro Plateau

Medications: Mounjaro · Wegovy · Ozempic · Zepbound

Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate

Compare: All Providers · Best GLP-1 Programs · All Guides